has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK’s RSV vaccine ...

GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to ...

GST registration in Haryana, Manipur, Meghalaya, and Tripura will now involve biometric Aadhaar authentication and document ...

Teva Pharmaceutical Industries Ltd. ADR-3.70% $19.56B ...

DualityBio entered into an exclusive $1 billion option agreement with GSK for DB-1324. Thermo Fisher Scientific completed its ...

Advisory for Biometric-Based Aadhaar Authentication and Document Verification for GST Registration Applicants of Haryana, Manipur, Meghalaya and Tripura This is to inform taxpayers about recent ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep (belantamab mafodotin) in combinations with bortezomib ...

It has also been sold in generic form by several other producers, some of which have also been named in litigation, including Boehringer Ingelheim, Pfizer, and Johnson & Johnson. GSK's settlement ...

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...